IN2013MN00441A - - Google Patents

Info

Publication number
IN2013MN00441A
IN2013MN00441A IN441MUN2013A IN2013MN00441A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A IN 441MUN2013 A IN441MUN2013 A IN 441MUN2013A IN 2013MN00441 A IN2013MN00441 A IN 2013MN00441A
Authority
IN
India
Prior art keywords
peptide
keratin
glucagon
type
assays
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2013MN00441A publication Critical patent/IN2013MN00441A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN441MUN2013 2010-10-07 2011-10-06 IN2013MN00441A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39099910P 2010-10-07 2010-10-07
PCT/US2011/055055 WO2012048082A2 (en) 2010-10-07 2011-10-06 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2013MN00441A true IN2013MN00441A (ru) 2015-05-29

Family

ID=45928428

Family Applications (1)

Application Number Title Priority Date Filing Date
IN441MUN2013 IN2013MN00441A (ru) 2010-10-07 2011-10-06

Country Status (12)

Country Link
US (1) US20130316370A1 (ru)
EP (2) EP3249402A1 (ru)
JP (3) JP2013539861A (ru)
CN (1) CN103238068B (ru)
AU (1) AU2011311997A1 (ru)
CA (1) CA2811438A1 (ru)
EA (1) EA201390293A1 (ru)
HK (1) HK1186248A1 (ru)
IN (1) IN2013MN00441A (ru)
MX (1) MX2013003662A (ru)
NZ (1) NZ608316A (ru)
WO (1) WO2012048082A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693738A1 (en) * 2013-09-20 2020-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
WO2015124707A1 (en) * 2014-02-20 2015-08-27 Immundiagnostik Ag In vitro diagnostic and prognosis of contrast induced nephropathy (cin) in patients undergoing coronary angiography
US11506672B2 (en) * 2015-06-11 2022-11-22 Astute Medical, Inc. Follistatin-related protein 3 for diagnosis and prognosis of renal injury and renal failure
CN106405064B (zh) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 一种40岁以上女性骨转换率的评估方法
JP7030834B2 (ja) * 2017-03-16 2022-03-07 深▲セン▼先進技術研究院 エネルギー代謝を調節するポリペプチド及びその使用
CN109468357A (zh) * 2018-12-25 2019-03-15 河北肽都生物科技有限公司 一种脾氨肽的制备方法
CN114269722A (zh) * 2019-07-26 2022-04-01 贝尔维奇生物医学研究所(伊迪贝尔) 麦角硫因、s-甲基-麦角硫因及其用途
CN113092768A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液角蛋白,ii型细胞骨架1及其多肽片段在过敏性疾病中的应用
CN113777304A (zh) * 2020-06-09 2021-12-10 张曼 尿液纤维蛋白溶解酶原及其多肽片段在烧伤中的应用
CN114264828B (zh) * 2022-01-28 2023-09-08 中国科学院基础医学与肿瘤研究所(筹) 鉴别良性甲状腺结节与甲状腺癌的生物标志物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
DE69231382T2 (de) 1991-04-12 2001-01-25 Biosite Diagnostics Inc., San Diego Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4487376B2 (ja) * 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
JP2002191398A (ja) * 2000-12-26 2002-07-09 Jenokkusu Soyaku Kenkyusho:Kk アレルギー性疾患検査方法
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005000194A2 (en) * 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US6941172B2 (en) * 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
JP2007532889A (ja) * 2004-04-16 2007-11-15 モナシュ ユニバーシティー 癌の進行度をモニタリングする方法
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
ES2703434T3 (es) * 2004-12-20 2019-03-08 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
US20070087387A1 (en) * 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
JP2007057509A (ja) * 2005-08-26 2007-03-08 Toray Ind Inc ネコアクチビンａの測定方法およびその測定キット
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
WO2007109809A1 (en) * 2006-03-23 2007-09-27 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
US7662578B2 (en) * 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
EP2479570A3 (en) * 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
WO2008150488A1 (en) * 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
WO2009039421A1 (en) * 2007-09-20 2009-03-26 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20110287964A1 (en) * 2008-11-17 2011-11-24 The Brigham And Women's Hospital, Inc. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans
MX2011005379A (es) * 2008-11-22 2011-06-09 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
WO2010091233A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Diagnosis and prognosis of renal injury and renal failure
US20120053072A1 (en) * 2009-02-06 2012-03-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140051754A (ko) * 2010-02-26 2014-05-02 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물

Also Published As

Publication number Publication date
EP2625524A2 (en) 2013-08-14
JP2018141793A (ja) 2018-09-13
JP2013539861A (ja) 2013-10-28
US20130316370A1 (en) 2013-11-28
CN103238068A (zh) 2013-08-07
JP6321080B2 (ja) 2018-05-09
CN103238068B (zh) 2016-06-08
CA2811438A1 (en) 2012-04-12
HK1186248A1 (zh) 2014-03-07
MX2013003662A (es) 2013-05-01
EA201390293A1 (ru) 2013-09-30
EP3249402A1 (en) 2017-11-29
WO2012048082A3 (en) 2012-06-21
JP2016180762A (ja) 2016-10-13
WO2012048082A2 (en) 2012-04-12
EP2625524A4 (en) 2014-05-07
AU2011311997A1 (en) 2013-04-04
NZ608316A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
IN2013MN00441A (ru)
Diedisheim et al. Modeling human pancreatic beta cell dedifferentiation
Chartoumpekis et al. Nrf2 represses FGF21 during long-term high-fat diet–induced obesity in mice
Elkhwanky et al. Obesity Represses CYP2R1, the Vitamin D 25 Hydroxylase, in the Liver and Extrahepatic Tissues
Hackett et al. The human airway epithelial basal cell transcriptome
Atkinson et al. C9ORF72 expression and cellular localization over mouse development
Barbosa-da-Silva et al. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice
Makki et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice
Li et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
BR112012007365A2 (pt) proteínas de ligação à il-1
Kuo et al. Induction of α cell–restricted Gc in dedifferentiating β cells contributes to stress-induced β cell dysfunction
MX2011004767A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
Camilleri et al. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion
WO2008060607A3 (en) Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
Dobarro et al. Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
MX353428B (es) Métodos y composiciones para identificar y tratar lupus.
Guo et al. JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression
WO2009101181A3 (en) Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
Wang et al. SFRP5 acts as a mature adipocyte marker but not as a regulator in adipogenesis
WO2009101059A3 (en) Methods of using cadherin 11 (cdh11) antagonists
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical